By Ana Espino | Published on February 12, 2026 | 3 min read
Autoimmune encephalitis (AE) refers to inflammatory disorders of
the central nervous system triggered by autoantibodies targeting neuronal
antigens. These conditions cause a broad spectrum of neuropsychiatric
symptoms, with acute epileptic seizures often being one of the earliest
and most prominent manifestations. In some patients, seizures persist beyond
the resolution of inflammation, evolving into chronic secondary epilepsy,
which can be drug-resistant.
Current management of AE relies on a
combination of immunotherapy and antiseizure drugs (ASDs). While this
approach typically controls the acute phase, it is insufficient to prevent
long-term seizure recurrence in a subset of patients. To date, no
protocol reliably predicts progression to chronic epilepsy, nor provides a
targeted means of preventing it. A major clinical challenge lies in identifying
patients at high risk of developing persistent epilepsy, understanding
the underlying mechanisms driving this transition, and developing tailored
strategies to anticipate and counter it.
Against this backdrop, this study
aimed to review current knowledge regarding the progression of acute
AE-related seizures to chronic epilepsy, by analyzing available clinical,
radiological, and immunological data, and by evaluating therapeutic
perspectives specific to this post-inflammatory epilepsy subtype.
Can we predict post-encephalitic epilepsy?
This narrative review synthesizes
clinical and experimental data on the evolution of seizures associated with AE.
It distinguishes between acute symptomatic seizures, autoimmune
status epilepticus (including NORSE and FIRES), and the transition toward defined
epilepsy as per ILAE criteria. The main types of autoantibodies examined
include anti-NMDAR, LGI1, GABA(B)R, CASPR2, and Hu.
Acute seizures are frequent at AE
onset, particularly in LGI1 and anti-GABA(B) forms, where over
80% of patients exhibit seizure activity. The risk of developing chronic
epilepsy depends on the antibody type: it is low in anti-NMDAR AE
but high in LGI1 and Hu-associated forms. The presence of structural
MRI abnormalities (e.g., atrophy, hippocampal damage), persistent
inflammation, and delayed treatment initiation are all factors
associated with a chronic course.
Patients who develop post-AE
epilepsy often show only partial response to conventional ASDs. The
concept of autoimmune-associated epilepsy (AAE) has been proposed to
define this distinct entity, which may require specialized, prolonged care,
potentially involving long-term immunotherapy or treatments aimed at residual
inflammation.
Toward prolonged and targeted management?
Autoimmune encephalitis is a potentially reversible brain
inflammatory disorder, but one that can lead to chronic, disabling epilepsy.
The central challenge lies in early identification of at-risk patients,
and the current lack of specific protocols to prevent seizure
chronicity.
This study aimed to clarify the mechanisms
and predictive factors underlying the transition from acute seizures to secondary
autoimmune epilepsy, and to explore possible targeted therapeutic
strategies. It confirms that early and precise intervention is
critical to reduce the risk of seizure persistence and to improve long-term
outcomes.
However, several limitations remain
and justify further research. These include the need for large multicenter longitudinal studies,
improved immunological and radiological patient characterization, and
the development of reliable predictive biomarkers. Future work should
also evaluate the role of long-term maintenance immunotherapy, establish
clear diagnostic criteria to distinguish between symptomatic seizures
and true autoimmune epilepsy, and promote personalized treatment strategies
based on each patient’s immunological profile.
About the author – Ana EspinoPhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication. 
